Clinical trial of the use of Annual SZ drug in the treatment of patients with Covid-19 disease in Emam Hosein hospital in Tehran.

INTERVENTION: Intervention 1: Intervention group: The group treated with Anval SZ + azithromycin Anval S is a herbal product derived from the herb. The active ingredient is artemisinin, which is used in the treatment of malaria. The dose of TDS is 1‐1.5 mg / kg. The time of use is 14 days for definite recovery, this medicine is in the form of oral syrup and is produced by the knowledge‐based university of the Health of Living Life, observing all health principles. Intervention 2: The group that receives treatment according to the national routine protocol + azithromycin. The drugs in this group are hydroxychloroquine and keltra. Chloroquine is an anti‐malarial drug and the dose is different depending on the phase of the disease and according to the national protocol. Hydroxychloroquine 200 mg daily for 8 days is administered as two stats together and then one every 12 hours for 5 days. About.Cltra tablets (lupinavir / ritonavir): 2 tablets of 50/200 every 12 hours for at least 5 days. CONDITION: COVID‐19. ; COVID‐19, virus not identified U07.2 PRIMARY OUTCOME: Blood oxygen level 93 and above ‐ People who have a blood oxygen level of less than 93 and get number one in the questionnaire. Timepoint: At the beginning of the study (before the intervention) and 3, 5, 7, 9, 11, 14 days after the start of use. Method of measurement: With digital pulse oximetry device. Coughs that have a score of one or more in the questionnaire. Timepoint: At the beginning of the study (before the intervention) and 3, 5, 7, 9, 11, 14 days after the start of use. Method of measurement: Based on the follow‐up and the patient's report. CRP that has a score of one or more in the questionnaire. Timepoint: On the day of starting (before treatment) 3, 5, 11 after starting treatment. Method of measurement: With the help of laboratory kit and agglutination method. Fever ‐ People who have a fever of more than 38 degrees and their score in the questionnaire is 1 or more than one. Timepoint: At the beginning of the study (before the intervention) and 3, 5, 7, 9, 11, 14 days after the start of use. Method of measurement: Mercury thermometer. HRCT that has a score of one or more based on the questionnaire. Timepoint: The first day before starting treatment and the 30th day after starting treatment. Method of measurement: With the help of CT scan machine. INCLUSION CRITERIA: pationt infected with covid19